Oncolytics Biotech reported ongoing work to extend pelareorep's patent protection, but gave no outcome or details. The filing alone does not show a change in the company's outlook.
The filing does not say that patent protection was extended or describe a new patent award. The company says the work is ongoing, so this update alone does not show a change in its outlook.
Follow Oncolytics Biotech Inc. (ONCY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ONCY